The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer
Dysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor in urothelial bladder cancer (UBC) progression. This...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Oncology Society
2024-07-01
|
| Series: | Journal of Urologic Oncology |
| Subjects: | |
| Online Access: | http://www.e-juo.org/upload/pdf/juo-244800460023.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850057080207048704 |
|---|---|
| author | Ho Kyung Seo Eui Hyun Jung Sora Yang Hye Won Lee |
| author_facet | Ho Kyung Seo Eui Hyun Jung Sora Yang Hye Won Lee |
| author_sort | Ho Kyung Seo |
| collection | DOAJ |
| description | Dysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor in urothelial bladder cancer (UBC) progression. This has led to the development of novel FGFR-targeted therapies. Erdafitinib is an oral selective pan-FGFR tyrosine kinase inhibitor approved for locally advanced or metastatic urothelial cancer in patients with FGFR3 alterations who progress on both platinum-based chemotherapy and immunotherapy. The approval of FGFR inhibitors (FGFRis), such as erdafitinib, and ongoing research into combination therapies with immune checkpoint inhibitors (ICIs) signify a promising shift in the treatment paradigm for advanced/metastatic UBC despite challenges such as the variable efficacy of FGFRis and treatment-related toxicity. In this study, we review the FGFR signaling pathway and the impact of altered FGFR signaling on UBC tumorigenesis, the clinical development of FGFRis, the rationale for FGFRi-ICI combinations, and future directions. |
| format | Article |
| id | doaj-art-814d6aaa75574176a8b48d74e48d1bb4 |
| institution | DOAJ |
| issn | 2951-603X 2982-7043 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Korean Urological Oncology Society |
| record_format | Article |
| series | Journal of Urologic Oncology |
| spelling | doaj-art-814d6aaa75574176a8b48d74e48d1bb42025-08-20T02:51:31ZengKorean Urological Oncology SocietyJournal of Urologic Oncology2951-603X2982-70432024-07-0122216617710.22465/juo.244800460023586The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder CancerHo Kyung Seo0Eui Hyun Jung1Sora Yang2Hye Won Lee3 Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Korea Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Korea Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Korea Department of Urology, Samsung Medical Center, Seoul, KoreaDysregulation of fibroblast growth factor (FGF)-receptor (FGFR) signaling, which is implicated in various oncogenic processes, including tumor proliferation, survival, migration, invasion, and angiogenesis, has been identified as a critical factor in urothelial bladder cancer (UBC) progression. This has led to the development of novel FGFR-targeted therapies. Erdafitinib is an oral selective pan-FGFR tyrosine kinase inhibitor approved for locally advanced or metastatic urothelial cancer in patients with FGFR3 alterations who progress on both platinum-based chemotherapy and immunotherapy. The approval of FGFR inhibitors (FGFRis), such as erdafitinib, and ongoing research into combination therapies with immune checkpoint inhibitors (ICIs) signify a promising shift in the treatment paradigm for advanced/metastatic UBC despite challenges such as the variable efficacy of FGFRis and treatment-related toxicity. In this study, we review the FGFR signaling pathway and the impact of altered FGFR signaling on UBC tumorigenesis, the clinical development of FGFRis, the rationale for FGFRi-ICI combinations, and future directions.http://www.e-juo.org/upload/pdf/juo-244800460023.pdfbladder cancerfibroblast growth factor receptorsfibroblast growth factor receptor inhibitor |
| spellingShingle | Ho Kyung Seo Eui Hyun Jung Sora Yang Hye Won Lee The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer Journal of Urologic Oncology bladder cancer fibroblast growth factor receptors fibroblast growth factor receptor inhibitor |
| title | The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer |
| title_full | The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer |
| title_fullStr | The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer |
| title_full_unstemmed | The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer |
| title_short | The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer |
| title_sort | role of fibroblast growth factor receptors inhibitors in bladder cancer |
| topic | bladder cancer fibroblast growth factor receptors fibroblast growth factor receptor inhibitor |
| url | http://www.e-juo.org/upload/pdf/juo-244800460023.pdf |
| work_keys_str_mv | AT hokyungseo theroleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT euihyunjung theroleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT sorayang theroleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT hyewonlee theroleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT hokyungseo roleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT euihyunjung roleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT sorayang roleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer AT hyewonlee roleoffibroblastgrowthfactorreceptorsinhibitorsinbladdercancer |